CDRH Scorecard Metric Determination. Presentation to the Balanced Scorecard Interest Group March 17, 2005
|
|
- Ralph Colin Wilson
- 6 years ago
- Views:
Transcription
1 CDRH Scorecard Metric Determination Presentation to the Balanced Scorecard Interest Group March 17, 2005
2 Organizational Structure DHHS FDA Food and Drug Administration Department of Health and Human Services ORA Office of Regulatory Affairs CBER Center for Biologics Evaluation and Research CDER Center for Drug Evaluation & Research CDRH Center for Devices and Radiological Health NCTR National Center for Toxiological Research CVM Center for Veterinary Medicine CFSAN Center for Food Safety and Applied Nutrition
3 CDRH Scorecard Development: 2000 CDRH Strategic Plan 2001 Determine Strategy 2002/2003 History Performance Scorecard Implementation 2004 Initiate process to Evaluate & Refine Scorecards
4 2002: Scorecard Development Process Collect Phase: Strategic Goals Determine obligations and commitments by reviewing Department and Agency documents
5 CDRH Strategic Goals Total Product Life Cycle Apply TPLC across Center activities to promote and protect the public health Public Health Impact Measure and communicate our impact on the public health Magnet for Excellence Attract and retain a diverse workforce to accomplish our public health mission Knowledge Management Manage knowledge to support TPLC in the information age
6 Obligations and Commitments President s Management Agenda One HHS Science Review Recommendations GPRA Goals Performance Plans (Commissioner & SES)
7 Create Phase: Develop Executive & Office Scorecards Each Office reviewed their core processes and proposed metrics which would be key indicators of success Philosophy: need an indicator for every process within our Office
8 2003 CDRH Executive Scorecard Key Result Areas (KRA s): 1. Public Health Promotion 2. Public Health Protection 3. Organizational Accountability 4. Stakeholder Collaboration 5. Workforce Excellence 6. Strategic Direction
9 FY-02/03 Metric Development CDRH Executive SC - Public Health Promotion (Expedited Approvals) 1. Average total elapsed days for approval 2. Average total elapsed time for final decisions 3. # of Expedited Applications 4. Average "Public Health Impact Score" based on population affected and risk reduction 5. # of agreement, determination, and other pre- submission meetings 6. % of Investigational Device Exemptions approved in the first 30-day cycle 7. % of submissions citing guidance or recognized standards
10 Office Scorecard Average total elapsed time for approval Median total elapsed time for device application approvals (1) expedited Pre-Market Approval (PMA) originals & expedited panel track PMA Supplements, (2) expedited 510(k)s, (3) Humanitarian Device Exemptions (HDEs( HDEs).
11 FY-02/03 Metric Development CDRH Executive SC Workforce Excellence 1. % CDRH employees receiving training 2. Average # of training hours per employee 3. % of CDRH managers completing core competency requirements 4. % of CDRH employees utilizing distance learning 5. # of CDRH employees participating in leadership programs 6. External Expertise Ratio (# of external engagements/ opportunities for engagements)
12 Office Level % CDRH employees receiving training 1. Staff College programs (in-house) 2. university/college courses 3. professional training programs 4. details 5. sabbaticals 6. fellowships 7. distance learning 8. mentoring 9. professional conferences..
13 2003 Executive & Office Scorecards Cultivate Phase: Gather, display, analyze historical data Did not have systems in place to capture all proposed metrics Reported what was available instead of developing systems to capture data
14 Performance Management System Vision, Mission, Core Values, And Core Passions Refinements Review, Evaluate, And Improve Business Performance Management System Rewards And Recognition Organization-Wide Strategic Planning Process Annual Deployment Cycle Workgroup And Individual Performance Management Process Develop Organization-Wide Performance Scorecard Management Cascade Operating Plans, Budget, And Scorecard Cascading Process Foundations For Achieving Performance Results Teaming System And Skills Process Improvement System And Skills Leadership Development System And Skills Project Management System And Skills Richard Chang Associates
15 Assessed Current Reality Disconnect between Scorecard Measures and Measures used to Manage Workload MDUFMA* Goals data had to be hand calculated from numerous data queries Data systems were not Centralized which impacted on data roll-up Medical Device User Fee and Modernization Act
16 2005 CDRH Executive Scorecard Key Result Areas (KRA s): 1. Public Health Promotion 2. Public Health Protection 3. Effective Management 4. Knowledge Management & Stakeholder Collaboration 5. Workforce Excellence
17 FY-04/05 Metric Development Collect Phase: Determine and prioritize obligations and commitments by reviewing Department and Agency documents Highest priority: MDUFMA requirements GPRA Goals and other Budget Document Obligations
18 Prioritization Goal Statement $ & Strategic Plans Ag. $ FDA CDRH Ctr. Perf. Plans Com MDUFMA 1. Utilize Risk management to target inspection coverage for Class II and Class III domestic medical device manufacturers at 20% or an estimate 5,500 firms. (Also FY 05 Goal-Only the Performance Plan specifies the target percentage) #11 2. Conduct 295 domestic and foreign BIMO inspections with an emphasis on scientific misconduct, data integrity, innovative products, and vulnerable populations. (Also FY 05 Goal) # Complete Review and Decision on premarket FY 2004 actions defined in the MDUFMA Legislation (MDUFMA) 4. Work with Stakeholders to implement MDUFMA. This will include providing MDUFMA training by December (MDUFMA)
19 FY-04/05 Metric Development CDRH Executive SC - Public Health Promotion 1. % on-time decisions and actions 2. % of Investigational Device Exemptions approved in the first 30-day cycle 3. % on-time consults
20 FY-04/05 Metric Development CDRH Executive SC Workforce Excellence 1. Average # of training hours per employee (limited to formal training & conferences) 2. # employees meeting training target 3. % of CDRH managers completing core competency requirements 4. % of operational dollars used for external expertise
21 Utilized the Performance Management System Concept to Assign Resources and Track Progress Project Management Developed Milestones Automate: target funds toward modifying or developing systems to capture high priority metrics Centralize Data Systems: internal benchmarking to develop efficient and productive systems
22 Lessons Learned Assess what is important to Stakeholders & Customers Periodic & Systematic Review Prioritize Systematic Implementation
23 Questions? Questions Comments? Frances A. Benedict
FDA Nanotechnology Regulatory Science Program Science Board Presentation August 2010
FDA Nanotechnology Regulatory Science Program Science Board Presentation August 2010 FDA Nanotechnology Task Force Carlos Peña, PhD Office of the Commissioner & Subhas Malghan, PhD Center for Devices and
More informationNavigating the FDA, and understanding Medical Device Preemption. Special Counsel Foulston Siefkin
Navigating the FDA, and understanding Medical Device Preemption Presented by Cydney Boler Special Counsel Foulston Siefkin cboler@foulston.com 913-253-2158 March 9, 2010 A bit of Legalese upfront: The
More informationMedical Device Labeling HealthPack 2004 Program
Medical Device Labeling HealthPack 2004 Program Elizabeth Kempen Overview Regulatory Agencies and Pathways Labeling Regulations General Medical Device Labeling Requirements Electronic Labeling FDA s Current
More informationRegulatory Approach to Nanotechnology-Based Drugs For Animals
Regulatory Approach to Nanotechnology-Based Drugs For Animals Steven Fleischer, DVM CSL/JIFSAN Joint Symposium on Food Safety and Nutrition: Nanotechnology in Foods and Cosmetics June 28, 2007 Introduction
More informationTina Morrison, Ph.D. Chair, Committee on Modeling and Simulation Office of the Chief Scientist U.S. Food and Drug Administration
Tina Morrison, Ph.D. Chair, Committee on Modeling and Simulation Office of the Chief Scientist U.S. Food and Drug Administration Tina.Morrison@fda.hhs.gov Joseph Pellettiere Overview FDA s Strategic Plan
More informationThe Role of Chemists in the FDA Drug Approval Process
The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006 Introduction Presentation Outline FDA Organization CDER Organization
More informationFDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond
FDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond Jeff Shuren, MD, JD Center for Devices and Radiological Health U.S. Food and Drug Administration May 4, 2017 1
More informationPreparing for a United States Food and Drug Administration (FDA) Inspection: VOICE
Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE This project has been funded in whole or in part with Federal funds from the Division of AIDS (DAIDS), National Institute
More informationFDA Drug Compliance. Pepe Rodriguez-Perez, PhD Business Excellence Consulting Inc / BEC Spain SL.
FDA Drug Compliance Presented by Pepe Rodriguez-Perez, PhD Business Excellence Consulting Inc / BEC Spain SL www.calidadpr.com email pepe@calidadpr.com Agenda 1. FDA s Strategic Priorities 2014-18 2. CDER
More informationWORKGROUP-LEVEL OVERVIEW. What You Will Learn. What You Will Apply To Your Workgroup
INTRODUCTION TO PERFORMANCE SCORECARDS WORKGROUP-LEVEL OVERVIEW What You Will Learn 1. By implementing Performance Scorecards, you are adopting an organized, proven method of defining key business outcomes
More informationEnhancing Staff Training for New Medical Device Reviewers
Enhancing Staff Training for New Medical Device Reviewers Carole C. Carey, BSEE, MEng. carole.carey@fda.hhs.gov Center for Devices and Radiological Health U.S. Food and Drug Administration TOPICS Addressing
More informationThe FDA/CDRH Perspective in the Regulation of Surgical Mesh
The FDA/CDRH Perspective in the Regulation of Surgical Mesh David Krause, Ph.D., Branch Chief Plastic & Reconstructive Surgery Branch Division of Surgical, Orthopedic & Restorative Devices Office of Device
More informationStatistical Computing Challenges at FDA. Paul Schuette, Ph.D. Scientific Computing Coordinator Office of Biostatistics FDA/CDER/OTS
Statistical Computing Challenges at FDA Paul Schuette, Ph.D. Scientific Computing Coordinator Office of Biostatistics FDA/CDER/OTS What does the FDA do? FDA is responsible for protecting the public health
More informationSTRATEGIC PLAN. Tier 2 Strategic Planning
STRATEGIC PLAN Tier 2 Strategic Planning December 2018 Tier 2 Strategic Planning All Tier 2 plans replicate the balanced scorecard framework and involve a strategy map. Two formats may be used for a Tier
More informationMy Experiences as an FDA Statistician
My Experiences as an FDA Statistician Yeh-Fong Chen, Ph.D. FDA/CDER/OB/DB3 CBA 2016-2017 Workshop series-3 Dec. 18, 2016 Disclaimer This presentation reflects the views of the author and should not be
More informationInspection Prioritization
FDA s Risk Toolbox: Inspection and Sampling Prioritization January 2011 Amy Barringer Division Director, Field Programs and Guidance FDA/CFSAN/Office of Compliance Inspection Prioritization 2 1 BACKGROUND
More informationFDA Regulation of In Vitro Diagnostics: Current Perspectives and Initiatives
FDA Regulation of In Vitro Diagnostics: Current Perspectives and Initiatives Katherine Donigan, Ph.D. Office of In Vitro Diagnostics and Radiological Health, FDA Life Science Tennessee Annual Conference
More informationUNIVERSITY OF COLORADO DEPARTMENT OF INTERNAL AUDIT 2018 AUDIT PLAN As of June 1, 2017
UNIVERSITY OF COLORADO DEPARTMENT OF INTERNAL AUDIT 2018 AUDIT PLAN As of June 1, 2017 Table of Contents I. Purpose 1 II. Internal Audit s Role, Objectives and Operational Strategy 1 III. Challenges and
More informationCascading the BSC Using the Nine Steps to Success
Cascading the BSC Using the Nine Steps to Success The Balanced Scorecard Institute uses a proven, disciplined framework, Nine Steps to Success, to systematically develop, implement, and sustain a strategic
More informationVISION, MISSION, VALUES
VISION, MISSION, VALUES Vision Statement: Through a combination of best practices and well established strategic partnerships, the Department of Human Resources will recruit, develop, and support the diverse
More informationFDA Regulatory Updates: Related to Cancer Immunotherapy
FDA Regulatory Updates: Related to Cancer Immunotherapy Society for Immunotherapy of Cancer (SITC) Raj K. Puri, M.D., Ph.D. Director, DCGT Office of Cellular, Tissue and Gene Therapies, FDA, CBER Date:
More informationFY2018 FY2021 Strategic Plan
FY2018 FY2021 Strategic Plan It is the mission of the City of Virginia Beach Emergency Communications and Citizen Services operations and administration to provide efficient, accurate, professional processing
More informationU.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE. Jeff Shuren Director Center for Devices and Radiological Health
U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE Jeff Shuren Director Center for Devices and Radiological Health 21 st Century Cures Implementation Establish Breakthrough Device Pathway Change
More informationCDER Keynote Address. Patrizia Cavazzoni M.D. Deputy Center Director for Operations CDER/FDA. AAM GRx+Biosims Conference September 5, 2018
CDER Keynote Address Patrizia Cavazzoni M.D. Deputy Center Director for Operations CDER/FDA AAM GRx+Biosims Conference September 5, 2018 1 Outline CDER s modernization roadmap Initiatives to facilitate
More informationGuidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationGuidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationAchieving Performance Excellence
Achieving Performance Excellence Baldrige 101 Workshop ASQ Professional Development Summit Today s Discussion Introduce the Baldrige framework Value and Benefits of Baldrige Regional Program MN, ND & SD
More informationSec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.
H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO
More informationVoluntary Pilot Meeting Preview: How will CDRH apply assessments in the voluntary program?
Voluntary Pilot Meeting Preview: How will CDRH apply assessments in the voluntary program? Cisco Vicenty Case for Quality Program Manager Center for Devices and Radiological Health U.S. Food and Drug Administration,
More informationAssociation of Food & Drug Officials (AFDO) Drug and Device Session. June 5, 2012
Association of Food & Drug Officials (AFDO) June 5, 2012 Drug and Device Session Presentation by: CAPT Domenic J. Veneziano Director, Division of Import Operations and Policy PRESENTATION OVERVIEW I. General
More informationFood and Drug Administration (FDA) 101
Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the
More informationPaths to Market & FDA Product Lifecycle Regulation. Patricia Kaeding Design of Medical Devices University of Minnesota April 14, 2005
Paths to Market & FDA Product Lifecycle Regulation Patricia Kaeding Design of Medical Devices University of Minnesota April 14, 2005 FDA Organization U.S. Food & Drug Administration Headed by a Commissioner
More informationData Transparency and Quality Metrics
Data Transparency and Quality Metrics Ann Ferriter Division of Analysis and Program Operations Office of Compliance Center for Devices and Radiological Health Why are we interested in transparency? What
More informationGuidance for IRBs, Clinical Investigators and Sponsors
Guidance for IRBs, Clinical Investigators and Sponsors IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is
More informationGood Governance and Anti-Corruption: The Role of Supreme Audit Institutions (SAIs)
Good Governance and Anti-Corruption: The Role of Supreme Audit Institutions (SAIs) Phillip Herr, Ph.D. Managing Director, Physical Infrastructure Issues U.S. Government Accountability Office The Vision
More informationPlans for Competency-Based Human Resources Management in KINS
Plans for -Based Human Resources Management in KINS May 13, 2014 Young-Joon CHOI, Head Human Resources Development Department International Nuclear Safety School Contents I. Backgrounds II. What is a competency?
More informationExcellence in Action: Division of Human Resources Summary Response to the Human Resources Assessment. Division of Human Resources
Excellence in Action: Division of Human Resources Summary to the Human Resources Assessment Division of Human Resources March 26, 2010 Introduction The Human Resources Assessment was conducted in response
More informationIPMA-CANADA INTERNATIONAL CERTIFICATION PROGRAM IPMA-CP (IN TRAINING) IPMA-CP IPMA-ACP IPMA-EX IPMA-CE
IPMA- Canada INTERNATIONAL PROGRAM IPMA-CP (IN TRAINING) IPMA-CP IPMA-ACP IPMA-EX IPMA-CE INTERNATIONAL PROGRAM is a national human resource management association whose mission is to promote excellence
More informationRainforest Strategies
Rainforest Strategies British Columbia s Innovation Ecosystem 03 October 2018 Webinar: TechDev 101 1 Rainforest Strategies Innovation Frontera JoeSterling@RFS-LLP.com +1-619-206-2403 www.rfs-llp.com 27
More informationThe Future of Drug Safety
The Future of Drug Safety IOM Committee on the Assessment of the US Drug Safety System R. Alta Charo Warren P. Knowles Professor of Law & Bioethics University of Wisconsin Charge to the Committee Examine
More informationCDRH s Inspection Strategy for 2018: How it Will Impact Your Company
CDRH s Inspection Strategy for 2018: How it Will Impact Your Company CAPT Sean M. Boyd, MPH, USPHS Deputy Director for Regulatory Affairs CDRH Office of Compliance Patients are at the Heart of What We
More informationDisclosures 4/2/2011. No conflict of interest Not representing any organization Not a billing consultant
San Francisco Radiation Oncology Conference April 2, 2011 Accelerated Partial Breast Irradiation: The Conundrum of Regulation and Reimbursement Disclosures No conflict of interest Not representing any
More informationIssues in Clinical Trial Designs for Devices
Issues in Clinical Trial Designs for Devices Soma Kalb, PhD Director, Investigational Device Exemption (IDE) Program Office of Device Evaluation Center for Devices and Radiological Health FDA Clinical
More informationStrategic Plan The OSC: A 21 st Century Securities Regulator
2012-2015 Strategic Plan The OSC: A 21 st Century Securities Regulator 2 The Ontario Securities Commission (OSC) is the regulatory body responsible for overseeing Ontario s capital markets, which include
More informationBipartisan Policy Center, Top Medical Innovation Priorities
Bipartisan Policy Center, Top Medical Priorities FDA: Advancing Medical is a Bipartisan Policy Center initiative led by former Senator Bill Frist, MD, former Congressman Bart Gordon, and BPC Health Initiative
More informationCarrie McMahon, Ph.D. Center for Food Safety and Applied Nutrition Office of Food Additive Safety. October 14, 2015
Carrie McMahon, Ph.D. Center for Food Safety and Applied Nutrition Office of Food Additive Safety October 14, 2015 FDA s Oversight of Food and Feed Safety food safety requirements how food safety requirements
More informationCOMBINATION PRODUCTS Inspection Readiness and Outcomes
WHITE PAPER COMBINATION PRODUCTS Inspection Readiness and Outcomes Many companies think that because they have a good relationship with the FDA Center they interacted with during their submission reviews
More informationHR Excellence. Confederation of Indian Industry
HR Excellence HR Excellence Assessment Model 2010 Leadership Broad Parameters Human Resource Strategy HR Management & Processes People Knowledge & Competencies People well being & engagement Results Perception
More informationFuture of Pharmaceutical Quality and the Path to Get There
Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 3rd PQRI/FDA Conference on Advancing
More informationStrategic Plan
Strategic Plan 2017-2019 THE NATIONAL GRADUATE SCHOOL OF QUALITY MANAGEMENT Celebrating 20 YEARS of Quality Education This material is protected by United States copyright laws. You must treat this publication
More informationGuidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application
Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application DRAFT GUIDANCE This guidance is being distributed for comment purposes only. Comments and suggestions regarding
More informationBuilding a Government Balanced Scorecard. Phase 1 - Planning
Building a Government Balanced Scorecard Phase 1 - Planning Paul Arveson The Balanced Scorecard Institute March 2003 2003 Balanced Scorecard Institute 1 Example of a Government Balanced Scorecard Implementation
More informationStrategic & Operational Plan
2015 2017 Strategic & Operational Plan 1 Strategic Plan Vision Statement: The elimination of occupational injury and illness in Saskatchewan. Mission Statement: To ensure the execution of an integrated
More informationUpdate on Current FDA Policies and Priorities
Update on Current FDA Policies and Priorities Vernessa Pollard MassMEDIC FDA Update December 12, 2017 Boston Brussels Chicago Dallas Düsseldorf Frankfurt Houston London Los Angeles Miami Milan Munich New
More informationExpanding Leadership and Substantive Skills of Statistical Agency Personnel Panel Discussion
Expanding Leadership and Substantive Skills of Statistical Agency Personnel Panel Discussion Lisa M. LaVange, PhD Director, Office of Biostatistics OTS/CDER/FDA FCSM Policy Seminar Washington, D.C. Dec.
More informationRole of the FDA and PDUFA in Drug Development
Role of the FDA and PDUFA in Drug Development Questions to be addressed 1. What is the Food and Drug Administration and why is it important? 2. Why was the Prescription Drug User Fee Act (PDUFA) created?
More informationGuidance for Industry - Computerized Systems Used in Clinical Trials
Page 1 of 14 Regulatory Information Computerized Systems Used in Clinical Trials Guidance for Industry - Computerized Systems Used in Clinical Trials
More informationFAA PMIWDC LUNCHEON SERIES STRATEGIC PLANNING; WHAT, WHY, AND HOW
FAA PMIWDC LUNCHEON SERIES STRATEGIC PLANNING; WHAT, WHY, AND HOW John Lever, Managing g Partner The Lever Group February 29 th, 2012 vision mission strategy performance INTRODUCTION AND SESSION OVERVIEW
More informationThe Institute of Medicine FDA s Role in Ensuring Safe Food January 28, 2011 PREDICT
The Institute of Medicine FDA s Role in Ensuring Safe Food January 28, 2011 PREDICT Presentation by: CDR Domenic J. Veneziano, Director, Division of Import Operations Topics PREDICT (Predictive Risk-based
More informationMetropolitan St. Louis Sewer District. Strategic Business and Operating Plan Fiscal Years
Metropolitan St. Louis Sewer District Strategic Business and Operating Plan Fiscal Years 2013 2017 VISION STATEMENT Quality Service Always MISSION STATEMENT To protect the public s health, safety, and
More informationState of Office of Pharmaceutical Quality (OPQ) Address
State of Office of Pharmaceutical Quality (OPQ) Address Giuseppe Randazzo, M.S. Director, Office of Program and Regulatory Operations Office of Pharmaceutical Quality Center for Drug Evaluation and Research,
More informationBUSINESS ACCOMPLISHMENTS CONSUMER PROTECTION
BUSINESS ACCOMPLISHMENTS 2016-2017 CONSUMER PROTECTION Goal: To regulate and enforce the legislation by which the Ontario travelling public can be confi dent in their travel purchases, including working
More informationGovernment-Wide Diversity and Inclusion Strategic Plan 2011
Government-Wide Diversity and Inclusion Strategic Plan 2011 Our Nation derives strength from the diversity of its population and from its commitment to equal opportunity for all. We are at our best when
More informationSTRATEGIC PLAN. FY
STRATEGIC PLAN FY 2017-2021 www.flynaples.com Adopted June 15, 2017 NAPLES AIRPORT AUTHORITY BOARD OF COMMISSIONERS Dick Evans Vice Chair Naples Airport began operation in 1943 as a military airfield.
More informationTHE CULTURE CANVAS A Working Guide and Checklist to Support the Development of a High-Performing Culture
denison TM THE CULTURE CANVAS A Working Guide and Checklist to Support the Development of a High-Performing Culture The Denison Model of High Performance A Systems Approach to Understanding and Managing
More informationIPMA-Canada Certification Program
Program IPMA-CP (In Training) IPMA-CP IPMA-ACP IPMA-EX IPMA-CE International Personnel Management Association Canada 3333 333 Program IPMA-Canada is a national human resource management association whose
More informationNovember CFPB Diversity and Inclusion Strategic Plan
November 2016 CFPB Diversity and Inclusion Strategic Plan 2016-2020 Message from Richard Cordray Director of the CFPB At the Consumer Financial Protection Bureau (CFPB), we are dedicated to making sure
More informationThe Brave New World of Medical Devices
The Brave New World of Medical Devices December 17, 2014 BOSTON GERMANY ISRAEL www.bmtadvisors.com www.bmtcrogroup.com 1 It Is All About The Adoption More Than a Mantra David Barone December 17, 2014 www.bmtadvisors.com
More informationCERTIFICATIONS IN HUMAN RESOURCES. SPHRi TM Senior Professional in Human Resources - International TM SPHRi. Exam Content Outline
CERTIFICATIONS IN HUMAN RESOURCES SPHRi TM Senior Professional in Human Resources - International TM 2018 SPHRi Exam Content Outline SPHRi Exam Content Outline At-a-Glance: SPHRi Exam Weighting by Functional
More informationShow value by learning to align initiatives, collecting data, and demonstrating the impact on business results. HUMAN CAPITAL. 30 T+D September 2013
HUMAN CAPITAL Show value by learning to align initiatives, collecting data, and demonstrating the impact on business results. 30 T+D September 2013 PHOTO: JENNI SWEITZER podcast examining INTEGRATED TALENT
More informationOrganizational Change Through Metrics
Organizational Change Through Metrics Speaker: Allen Hurst and Heather Rainey Company: Improving Enterprises Website: www.improvingenterprises.com Welcome to the PMI Houston Conference & Expo 2015 Please
More informationCenter for Drug Evaluation and Research. CDER Small Business and Industry Assistance. (CDER SBIA) and New Drug Review.
Center for Drug Evaluation and Research Small Business and Industry Assistance (CDER SBIA) and New Drug Review LT Renu Lal, Pharm.D. CDER Small Business and Industry Assistance Division of Drug Information
More informationPHARM 532 Regulation of Pharmaceuticals II
FDA s Regulatory Structuret PHARM 532 Regulation of Pharmaceuticals II Spring 2009 Center(s) for Biologics Evaluation & Research (CBER) 1 Drug Evaluation & Research (CDER) 2 Device & Radiological Health
More informationObjective Standards Of Performance
Objective Standards Of Performance Introduction...1 Section A - Laboratory Leadership...2 Section B Science And Technology...5 Section C - Performance Objectives, Criteria And Measures...7 1 Environment,
More informationGuidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations
Guidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations DRAFT GUIDANCE This draft guidance document is being distributed for comment purposes only.
More informationSupply Management Three-Year Strategic Plan
Supply Management Three-Year Strategic Plan 2010-2012 Message From the Vice President, Supply Management I am pleased to present our new three-year strategic plan for fiscal years 2010 2012. The plan
More informationGW Human Resources Strategic Plan
GW Human Resources Strategic Plan 2017-2021 OUR VISION We aspire to develop a diverse and engaged workforce to lead GW to excellence. OUR MISSION The mission of Human Resources is: to serve as an effective
More informationDial-in Number: Access code: # Go to: Use the JOIN A SESSION button Enter the Access Code:
Dial-in Number: 209 647-1075 Access code: 1013004# Go to: http://www.gatherplace.net Use the JOIN A SESSION button Enter the Access Code: 8285433 This presentation may appear different on your computer
More informationGuidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order
Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order Document issued on: [Level 2, June 15, 2009] This guidance supersedes the document issued under this
More informationTitle: Review of Medical Devices Page: 1 of 5 Written by:
THE NORTH SHORE MEDICAL CENTER Institutional Review Board (IRB) POLICIES AND PROCEDURES IRB Policy Number: 031.1 Title: Review of Medical Devices Page: 1 of 5 Written by: Approved by: Laura W. Knight,
More informationFLORIDA DEPARTMENT OF HEALTH AGENCY WORKFORCE DEVELOPMENT IMPLEMENTATION PLAN
FLORIDA DEPARTMENT OF HEALTH AGENCY WORKFORCE DEVELOPMENT IMPLEMENTATION PLAN Mission To protect, promote and improve the health of all people in Florida through integrated state, county, and community
More informationLIFE SCIENCE BENCHMARKING STUDY. Trends and Best Practices Based on Our Work with the US FDA and Over 250 Companies
LIFE SCIENCE 01 BENCHMARKING STUDY Trends and Best Practices Based on Our Work with the US FDA and Over 0 Companies SUMMARY In this report, UL EduNeering has identified the 01/01 compliance and business
More informationOverview of USP Activities and How to Get Involved
Overview of USP Activities and How to Get Involved Ravi Ravichandran, Ph.D. Principal Scientific Liaison, Chemical Medicines United States Pharmacopeia Outline Introduction to the USP USP Standard Setting
More informationRecommendations for Strengthening the Investigator Site Community
Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials
More informationA conversation about the framework for performance excellence PERFORM LIKE A ROCK STAR!
A conversation about the framework for performance excellence PERFORM LIKE A ROCK STAR! Like Olympic athletes, pursing performance excellence in our work implies that we optimize every factor that goes
More informationFood and Drug Administration Guidance: Supervisory Responsibilities of Investigators
Journal of Diabetes Science and Technology Volume 5, Issue 2, March 2011 Diabetes Technology Society REVIEW ARTICLE Food and Drug Administration Guidance: Supervisory Responsibilities of Investigators
More informationStatus of Food and Drug Administration Programs and Activities During the Current Government Shutdown
Status of Food and Drug Administration Programs and Activities During the Current Government Shutdown Agency-Wide FDA can perform activities necessary to address imminent threats to the safety of human
More informationHuman Resources Strategic Update. Presented by Stephen Trncak October 28, 2011
Human Resources Strategic Update Presented by Stephen Trncak October 28, 2011 Agenda Past and Future for the College The End Game (Elevating the Human and Organizational Capabilities and Capacity of the
More informationCSR / Sustainability Governance and Management Assessment By Coro Strandberg President, Strandberg Consulting
Introduction CSR / Sustainability Governance and Management Assessment By Coro Strandberg President, Strandberg Consulting www.corostrandberg.com November 2015 Companies which adopt CSR or sustainability
More informationFDA Requirements for Clinical Investigations of Medical Devices: A Review for European Manufacturers
FDA Requirements for Clinical Investigations of Medical Devices: A Review for European Manufacturers Autumn Dawn Ediger, 1, * Birgit Limbach 2 and Dieter Dannhorn 3 1 Regulatory Affairs, Clinical QM and
More informationRe: Docket No. FDA 2015-D-1580:
August 17, 2015 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2015-D-1580: Patient Preference Information Submission,
More informationOffice of Pharmaceutical Quality Progress Update
Office of Pharmaceutical Quality Progress Update Michael Kopcha, Ph.D., R.Ph. Director Office of Pharmaceutical Quality CDER/FDA 2017 3 rd PQRI/FDA Conference on Advancing Product Quality March 22-24,
More informationMilestones & Benchmarks
2014 Center for Communities That Care, University of Washington Phase 1: Get Started 1.1 Organize the community to begin the Communities That Care Process. Designate a single point of contact to act as
More informationDoD ENVIRONMENTAL MANAGEMENT SYSTEM (EMS) METRICS FISCAL YEARS
DoD ENVIRONMENTAL MANAGEMENT SYSTEM (EMS) METRICS FISCAL YEARS 2009 2011 These metrics are identical to the Federal EMS Metrics and provide the mechanism by which DoD agencies, organizations and facilities
More informationNew Approach to Drug Inspections
New Approach to Drug Inspections Donald D. Ashley Director CDER Office of Compliance 2018 FDLI Annual Meeting May 4, 2018 Office of Compliance Structure Mission: The Office of Compliance shield s patients
More informationDocument issued on: March 19, The draft of this document was issued on May 20, 2010.
Reprinted from FDA s website by Guidance for Industry, Third Parties and Food and Drug Administration Staff Medical Device ISO 13485:2003 Voluntary Audit Report Submission Pilot Program Document issued
More informationMurray Sheldon, MD Associate Director for Technology and Innovation Center for Devices and Radiological Health (CDRH) Office of the Center Director
Murray Sheldon, MD Associate Director for Technology and Innovation Center for Devices and Radiological Health (CDRH) Office of the Center Director The National Academies Innovation Policy Forum September
More informationCharter for Enterprise Risk Management
for Enterprise Risk Management Prepared by: Shannon Sinclair Version: 1.2 Document Id: Date: Release Date TABLE OF CONTENTS TABLE OF CONTENTS... i 1. Background... 1 2. Objectives... 1 3. Scope... 2 3.1
More informationDeveloping Enterprise-Wide Measures for Tracking Performance of Acquisition Organizations
Pittsburgh, PA 15213-3890 Developing Enterprise-Wide Measures for Tracking Performance of Acquisition Organizations Wolfhart Goethert Carnegie Mellon University Pittsburgh, PA 15213-3890 Sponsored by the
More informationEvaluating and Building Portfolio Management Maturity
Evaluating and Building Portfolio Management Maturity Hostetter and Norris, UMD PM Symposium 2016 Evaluating and Building Portfolio Management Maturity Susan Hostetter and Sherri Norris U.S. Census Bureau,
More information